Impact of Study Design on Reported Incidences of Acute Mountain Sickness: A Systematic Review

High Altitude Medicine and Biology

Volumn 16, Issue 3, 2015, Pages 204-215

  Waeber, Baptiste ^a   Kayser, Bengt ^a,b   Dumont, Lionel ^c   Lysakowski, Christopher ^c   Tramèr, Martin R ^a,c   Elia, Nadia ^c,d  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

acute mountain sickness; altitude; cohort; cross sectional study; randomized controlled trial

Indexed keywords

ACUTE MOUNTAIN SICKNESS; ALTITUDE; ALTITUDE DISEASE; ARTICLE; BIBLIOGRAPHIC DATABASE; CASE CONTROL STUDY; CLINICAL ASSESSMENT; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; ENVIRONMENTAL EXPOSURE; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; MEDICAL HISTORY; MEDLINE; MULTIPLE LINEAR REGRESSION ANALYSIS; MULTIVARIATE ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEASONAL VARIATION; STUDY DESIGN; SYSTEMATIC REVIEW; ALTITUDE SICKNESS; FORECASTING; MEASUREMENT ACCURACY; METHODOLOGY; MOUNTAINEERING;

ALTITUDE; ALTITUDE SICKNESS; COHORT STUDIES; DATA ACCURACY; FORECASTING; HUMANS; INCIDENCE; MOUNTAINEERING; RESEARCH DESIGN;

EID: 84940933115     PISSN: 15270297     EISSN: 15578682     Source Type: Journal    
DOI: 10.1089/ham.2015.0022     Document Type: Article

References (140)

1. Alizadeh R, Ziaee V, Aghsaeifard Z, Mehrabi F, and Ahmadinejad T. (2012). Characteristics of headache at altitude among trekkers; A comparison between acute mountain sickness and non-Acute mountain sickness headache. Asian J Sports Med 3:126-130.
2. Alizadeh R, Ziaee V, Frooghifard L-A, Mansournia M-A, and Aghsaeifard Z. (2012). The effect of path and beginning time of ascending on incidence of acute mountain sickness around Mount Damavand in Iran (5671 m). Neurol Res Intl 2012: 428296.
3. Anderson PJ, Miller AD, OMalley KA, Ceridon ML, Beck KC, Wood CM, Wiste HJ, Mueller JJ, Johnson JB, and Johnson BD. (2011). Incidence and symptoms of high altitude illness in South Pole workers: Antarctic Study of Altitude Physiology (ASAP). Clin Med Insights Circ Respir Pulm Med 5:27-35.
4. Baillie JK, Thompson AAR, Irving JB, Bates MGD, Sutherland AI, Macnee W, Maxwell SRJ, and Webb DJ. (2009). Oral antioxidant supplementation does not prevent acute mountain sickness: Double blind, randomized placebo-controlled Trial. QJM: Monthly J Assoc Phys 102:341-348.
5. Bärtsch P, and Swenson ER. (2013). Clinical practice: Acute high-Altitude illnesses. N Engl J Med 368:2294-2302.
6. Basnyat B, Lemaster J, and Litch JA. (1999). Everest or bust: A cross sectional, epidemiological study of acute mountain sickness at 4243 meters in the Himalayas. Aviat Space Environ Med 70:867-873.
7. Basnyat B, and Litch JA. (1997). Medical problems of porters and trekkers in the Nepal Himalaya. Wild Environ Med 8:78-81.
8. Basnyat B, Subedi D, Sleggs J, Lemaster J, Bhasyal G, Aryal B, and Subedi N. (2000). Disoriented and ataxic pilgrims: An epidemiological study of acute mountain sickness and highaltitude cerebral edema at a sacred lake at 4300m in the Nepal Himalayas. Wild Environ Med 11:89-93.
9. Basnyat B, Gertsch JH, Holck PS, Johnson EW, Luks AM, Donham BP, Fleischman RJ, Gowder DW, Hawksworth JS, Jensen BT, Kleiman RJ, Loveridge AH, Lundeen EB, Newman SL, Boboa JA, Miegs DP, OBeirne KA, Philpot KB, Schultz MN, Valente MC, Wiebers MR, and Swenson ER. (2006). Acetazolamide 125 mg bd is not significantly different from 375 mg bd in the prevention of acute mountain sickness: The Prophylactic Acetazolamide Dosage Comparison for Efficacy (PACE) Trial. High Alt Med Biol 7:17-27.
10. Basnyat B, Gertsch JH, Johnson EW, Castro-Marin F, Inoue Y, and Yeh C. (2003). Efficacy of low-dose acetazolamide (125 mg bid) for the prophylaxis of acute mountain sickness: A prospective, double-blind, randomized, placebo-controlled trial. High Alt Med Biol 4:45-52.
11. Basnyat B, Hargrove J, Holck PS, Srivastav S, Alekh K, Ghimire LV, Pandey K, Griffiths A, Shankar R, Kaul K, Paudyal A, Stasiuk D, Basnyat R, Davis C, Southard A, Robinson C, Shandley T, Johnson DW, Zafren K, Williams S, Weiss EA, Farrar JJ, and Swenson ER. (2008). Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Alt Med Biol 9:209-216.
12. Basnyat B, Holck PS, Pun M, Halverson S, Szawarski P, Gertsch J, Steif M, Powell S, Khanal S, Joshi A, Shankar R, Karambay J, Alexander HD, Stone A, Morrissey C, Thompson BH, and Farrar JJ; SPACE Trial Group. (2011). Spironolactone does not prevent acute mountain sickness: A prospective, double-blind, randomized, placebo-controlled trial by SPACE Trial Group (Spironolactone and Acetazolamide Trial in the Prevention of Acute Mountain Sickness Group). Wilderness Environ Med 22:15-22.
13. Basnyat B, and Murdoch DR. (2003). High-Altitude illness. Lancet 361:1967-1974.
14. Bates M, Thompson AAR, Baillie JK, Sutherland AI, Irving JB, Hirani N, and Webb DJ. (2011). Sildenafil citrate for the prevention of high atitude hypoxic pulmonary hypertension: Double blind, randomized, placebo-controlled trial. High Alt Med Biol 12:207-214.
15. Beidleman BA, Fulco CS, Muza SR, Rock PB, Staab JE, Forte VA, Brothers MD, and Cymerman A. (2009). Effect of six days of staging on physiologic adjustments and acute mountain sickness during ascent to 4300 meters. High Alt Med Biol 10:253-260.
16. Beidleman BA, Muza SR, Fulco CS, Rock PB, and Cymerman A. (2007a). Validation of a shortened electronic version of the Environmental Symptoms Questionnaire. High Alt Med Biol 8:192-199.
17. Benson K, and Hartz AJ. (2000). A comparison of observational studies and randomized, controlled trials. N Engl J Med 342:1878-1886.
18. Bernhard WN, Schalick LM, and Gittelsohn A. (1994). Dexamethasone for prophylaxis against acute mountain sickness during rapid ascent to 5334 m. J Wilderness Med 5:331-338.
19. Bloch J, Duplain H, Rimoldi SF, Stuber T, Kriemler S, Allemann Y, Sartori C, and Scherrer U. (2009). Prevalence and time course of acute mountain sickness in older children and adolescents after rapid ascent to 3450 meters. Pediatrics 123:1-5.
20. Bosch MM, Barthelmes D, Merz TM, Bloch KE, Turk AJ, Hefti U, Sutter FKP, Maggiorini M, Wirth MG, Schoch OD, and Landau K. (2008). High incidence of optic disc swelling at very high altitudes. Arch Ophthalmol 126:644-650.
21. Brito J, Siqués P, León-Velarde F, De La Cruz JJ, López V, and Herruzo R. (2007). Chronic intermittent hypoxia at high altitude exposure for over 12 years: Assessment of hematological, cardiovascular, and renal effects. High Alt Med Biol 8:236-244.
22. Burki NK, Khan SA, and Hameed MA. (1992). The effects of acetazolamide on the ventilatory response to high altitude hypoxia. Chest 101:736-741.
23. Burse RL, Cymerman A, and Young AJ. (1987). Respiratory response and muscle function during isometric handgrip exercise at high altitude. Aviat Space Environ Med 58:39-46.
24. Carlsten C, Swenson ER, and Ruoss S. (2004). A dose-response study of acetazolamide for acute mountain sickness prophylaxis in vacationing tourists at 12, 000 feet (3630 m). High Alt Med Biology 5:33-39.
25. Castellani JW, Muza SR, Cheuvront SN, Sils IV, Fulco CS, Kenefick RW, Beidleman BA, and Sawka MN. (2010). Effect of hypohydration and altitude exposure on aerobic exercise performance and acute mountain sickness. J Appl Physiol 109:1792-1800.
26. Chen GZ, Qin J, Yu J, Gao XB, Dong JQ, Lu W, Bian SZ, Zeng Y, and Huang L. (2013). Incidence of acute mountain sickness in young adults at 3200 meters: Comparison of the Lake Louise Scoring and Chinese Scoring Systems. Genetics Mol Res 12:6790-6801.
27. Chen H-C, Lin W-L, Wu J-Y, Wang S-H, Chiu T-F, Weng YM, Hsu T-Y, and Wu M-H. (2012). Change in oxygen saturation does not predict acute mountain sickness on Jade Mountain. Wilderness Environ Med 23:122-127.
28. Chow T, Browne V, Heileson HL, Wallace D, Anholm J, and Green SM. (2005). Ginkgo biloba and acetazolamide prophylaxis for acute mountain sickness: A randomized, placebo-controlled trial. Arch Int Med 165:296-301.
29. Cymerman A, Muza SR, Beidleman BA, Ditzler DT, and Fulco CS. (2001). Postural instability and acute mountain sickness during exposure to 24 hours of simulated altitude (4300 m). High Alt Med Biol 2:509-514.
30. Dallimore J, and Rowbotham EC. (2009). Incidence of acute mountain sickness in adolescents. Wilderness Environ Med 20:221-224.
31. Davies AJ, Kalson NS, Stokes S, Earl MD, Whitehead AG, Frost H, Tyrell-Marsh I, and Naylor J. (2009). Determinants of summiting success and acute mountain sickness on Mt Kilimanjaro (5895m). Wilderness Environ Med 20:311-317.
32. Dehnert C, Weymann J, Montgomery HE, Woods D, Maggiorini M, Scherrer U, Gibbs JSR, and Bärtsch P. (2002). No association between high-Altitude tolerance and the ace i/d gene polymorphism. Med Sci Sports Exercise 34:1928-1933.
33. Dellasanta P, Gaillard S, Loutan L, and Kayser B. (2007). Comparing questionnaires for the assessment of acute mountain sickness. High Alt Med Biol 8:184-191.
34. Dicianno BE, Aguila ED, Cooper RA, Pasquina PF, Clark MJ, Collins DM, Fitzgerald SG, and Wichman TA. (2008). Acute mountain sickness in disability and adaptive sports: Preliminary data. J Rehab Res Develop 45:479-487.
35. Douglas DJ, and Schoene RB. (2010). End-Tidal partial pressure of carbon dioxide and acute mountain sickness in the first 24 hours upon ascent to Cusco Peru (3326 meters). Wilderness Environ Med 21:109-113.
36. Dubowitz G, and Peacock AJ. (2007). Pulmonary artery pressure in healthy subjects at 4250m measured by Doppler echocardiography. Wilderness Environ Med 18:305-311.
37. Dumont L, Mardirosoff C, and Tramèr MR. (2000). Efficacy and harm of pharmacological prevention of acute mountain sickness: Quantitative systematic review. BMJ (Clin Res Ed) 321:267-272.
38. Dumont L, Lysakowski C, Tramèr MR, Junod J-D, Mardirosoff C, Tassonyi E, and Kayser B. (2004). Magnesium for the prevention and treatment of acute mountain sickness. Clin Sci (London, England: 1979) 106:269-277.
39. Ellsworth AJ, Meyer EF, and Larson EB. (1991). Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med 154:289-293.
40. Ellsworth AJ, Larson EB, and Strickland D. (1987). A randomized trial of dexamethasone and acetazolamide for acute mountain sickness prophylaxis. Am J Med 83:1024-1030.
41. Erba P, Anastasi S, Senn O, Maggiorirni M, and Bloch KE. (2004). Acute mountain sickness is related to nocturnal hypoxemia but not to hypoventilation. Eur Respir J 24:303-308.
42. Fischer R, Vollmar C, Thiere M, Born C, Leitl M, Pfluger T, and Huber R. (2004). No evidence of cerebral oedema in severe acute mountain sickness. Cephalalgia 24:66-71.
43. Gaillard S, Dellasanta P, Loutan L, and Kayser B. (2004). Awareness, prevalence, medication use, and risk factors of acute mountain sickness in tourists trekking around the Annapurnas in Nepal: A 12-year follow-up. High Alt Med Biology 5:410-419.
44. Gertsch JH, Basnyat B, Johnson EW, Onopa J, and Holck PS. (2004). Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among himalayan trekkers: The Prevention of High Altitude Illness Trial (PHAIT). BMJ (Clin Res Ed) 328:797.
45. Gertsch JH, Corbett B, Holck PS, Mulcahy A, Watts M, Stillwagon NT, Casto AM, Abramson CH, Vaughan CP, Macguire C, Farzan NN, Vo BN, Norvelle RJ, May K, Holly JE, Irons H, Stutz AM, Chapagain P, Yadav S, Pun M, Farrar J, and Basnyat B. (2012). Altitude sickness in climbers and efficacy of NSAIDs Trial (ASCENT): Randomized, controlled trial of ibuprofen versus placebo for prevention of altitude illness. Wilderness Environ Med 23:307-315.
46. Gertsch JH, Lipman GS, Holck PS, Merritt A, Mulcahy A, Fisher RS, Basnyat B, Allison E, Hanzelka K, Hazan A, Meyers Z, Odegaard J, Pook B, Thompson M, Slomovic B, Wahlberg H, Wilshaw V, Weiss EA, and Zafren K. (2010). Prospective, Double-blind, randomized, placebo-controlled comparison of acetazolamide versus ibuprofen for prophylaxis against high altitude headache: The Headache Evaluation at Altitude Trial (HEAT). Wilderness Environ Med 21:236-243.
47. Gertsch JH, Seto TB, Mor J, and Onopa J. (2002). Ginkgo biloba for the prevention of severe acute mountain sickness (AMS) starting one day before rapid ascent. High Alt Med Biol 3:29-37.
48. Grissom CK, Richer LD, and Elstad MR. (2005). The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude. Chest 127:565-570.
49. Hackett PH, Rennie D, and Levine HD. (1976). The incidence, importance, and prophylaxis of acute mountain sickness. Lancet 2:1149-1155.
50. Hackett PH, and Roach RC. (2001). High-Altitude illness. N Engl J Med 345:107-114.
51. d Hillenbrand P, Pahari AK, Soon Y, Subedi D, Bajracharya R, Gurung P, Lal BK, Marahatta R, Pradhan S, Rai D, and Sharma S; Birmingham Medical Research Expeditionary Society. (2006). Prevention of acute mountain sickness by acetazolamide in Nepali porters: A double-blind controlled trial. Wilderness Environ Med 17:87-93.
52. Honigman B, Read M, Lezotte D, and Roach RC. (1995). Sealevel physical activity and acute mountain sickness at moderate altitude. West J Med 163:117-121.
53. Honigman B, Theis MK, Koziol-McLain J, Roach R, Yip R, Houston C, Moore LG, and Pearce P. (1993). Acute mountain sickness in a general tourist population at moderate altitudes. Ann Int Med 118:587-592.
54. Hooper TJ, Levett DZH, Mellor AJ, and Grocott MPW. (2010). Resting and exercising cardiorespiratory variables and acute mountain sickness. J Royal Naval Med Serv 96:6-12.
55. Imray C, Wright A, Subudhi A, and Roach R. (2010). Acute mountain sickness: pathophysiology, prevention, and treatment. Prog Cardiovasc Dis 52:467-484.
56. Imray CHE, Kennedy CH, Pattinson K, Brearey S, and Wright A. (2004). Self-Assessment of acute mountain sickness in adolescents: A pilot study. Wilderness Environ Med 15:202-206.
57. Jackson SJ, Varley J, Sellers C, Josephs K, Codrington L, Duke G, Njelekela MA, Drummond G, Sutherland AI, Thompson AA, and Baillie JK. (2010).Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro. High Alt Med Biol 11:217-222.
58. Jafarian S, Gorouhi F, and Lotfi J. (2007). Reverse association between high-Altitude headache and nasal congestion. Cephalalgia 27:899-903.
59. Jafarian S, Gorouhi F, Salimi S, and Lotfi J. (2007).Sumatriptan for prevention of acute mountain sickness: Randomized clinical trial. Ann Neurol 62:273-277.
60. Jafarian S, Gorouhi F, Taghva A, and Lotfi J. (2008). Highaltitude sleep disturbance: Results of the Groningen Sleep Quality Questionnaire Survey. Sleep Med 9:446-449.
61. Johnson PL, Popa DA, Prisk GK, Edwards N, and Sullivan CE. (2010). Non-Invasive positive pressure ventilation during sleep at 3800 m: Relationship to acute mountain sickness and sleeping oxyhaemoglobin saturation. Respirology (Carlton, Vic.) 15:277-282.
62. Kamat SR, and Banerji BC. (1972). Study of cardiopulmonary function on exposure to high altitude. I. Acute acclimatization to an altitude of 3, 5000 to 4, 000 meters in relation to altitude sickness and cardiopulmonary function. Am Rev Respirat Dis 106: 404-413.
63. Kao W-F, Kuo CC, Hsu T-F, Chang H, Sung Y-Y, Yen DHT, Wu J-K, and Lee C-H. (2002). Acute mountain sickness in Jade Mountain climbers of Taiwan. Aviat Space Environ Med 73:359-362.
64. Karinen H, Peltonen J, and Tikkanen H. (2008). Prevalence of acute mountain sickness among Finnish trekkers on Mount Kilimanjaro, Tanzania: An observational study. High Alt Med Biology 9:301-306.
65. Kayser B, Aliverti A, Pellegrino R, Dellaca R, Quaranta M, Pompilio P, Miserocchi G, and Cogo A. (2010).Comparison of a Visual Analogue Scale and Lake Louise Symptom Scores for acute mountain sickness. High Alt Med Biol 11:69-72.
66. Kayser B, Dumont L, Lysakowski C, Combescure C, Haller G, and Tramèr MR. (2012). Reappraisal of acetazolamide for the prevention of acute mountain sickness: A systematic review and meta-Analysis. High Alt Med Biol 13:82-92.
67. Kayser B, Hulsebosch R, and Bosch F. (2008). Low-dose acetylsalicylic acid analog and acetazolamide for prevention of acute mountain sickness. High Alt Med Biol 9: 15-23.
68. Kronenberg RS, and Cain SM. (1967). Hastening respiratory acclimatization to altitude with benzolamide. In: Biomedical Problems of High Terrestrial Elevations, edited by A.H. Hegnauer, Springfield, VA: Clearing House Fed Sci Tech Info. pp. 57-63.
69. Küpper TEAH, Strohl KP, Hoefer M, Gieseler U, Netzer CM, and Netzer NC. (2008). Low-dose theophylline reduces symptoms of acute mountain sickness. J Travel Med 15:307-314.
70. Lalande S, Anderson PJ, Miller AD, Ceridon ML, Beck KC, OMalley KA, Johnson JB, and Johnson BD. (2011). Variability in pulmonary function following rapid altitude ascent to the Amundsen-Scott South Pole Station. Eur J Appl Physiol 111:2221-2228.
71. Larson EB, Roach RC, Schoene RB, and Hornbein TF. (1982). Acute mountain sickness and acetazolamide. Clinical efficacy and effect on ventilation. JAMA 288:328-332.
72. Leadbetter G, Keyes LE, Maakestad KM, Olson S, Tissot van Patot MC, and Hackett PH. (2009). Ginkgo biloba does-And does not-prevent acute mountain sickness. Wilderness Environ Med 20:66-71.
73. Li F-X, Ji F-Y, Zheng S-Z, Yao W, Xiao Z-L, and Qian G-S. (2011). MtDNA haplogroups M7 and B in Southwestern Han Chinese at risk for acute mountain sickness. Mitochondrion 11:553-558.
74. Li X, Tao F, Pei T, You H, Liu Y, and Gao Y. (2011a). Population level determinants of acute mountain sickness among young men: A retrospective study. BMC Public Health 11:740.
75. Li X, Tao F, You H, Pei T, and Gao Y. (2011b). Factors associated with acute mountain sickness in young Chinese men on entering highland areas. Asia Pac J Public Health. 2015 Mar;27(2):NP116-31. doi: 10.1177/1010539511427956.Epub 2011 Dec 20.
76. Lipman GS, Kanaan NC, Holck PS, Constance BB, Gertsch JH, and PAINS Group. (2012). Ibuprofen prevents altitude illness: A randomized controlled trial for prevention of altitude illness with nonsteroidal anti-inflammatories. Ann Emerg Med 59:484-490.
77. Lyons TP, Muza SR, Rock PB, and Cymerman A. (1995). The effect of altitude pre-Acclimatization on acute mountain sickness during reexposure. Aviat Space Environ Med 66: 957-962.
78. MacInnis MJ, Lohse KR, Strong JK, and Koehle MS. (2013).Is previous history a reliable predictor for acute mountain sickness susceptibility? A meta-Analysis of diagnostic accuracy. Br J Sports Med 14:334-337.
79. MacInnis MJ, Koehle MS, and Rupert JL. (2010). Evidence for a genetic basis for altitude illness: 2010 update. High Alt Med Biol 11:349-368.
80. Maggiorini M, Bühler B, Walter M, and Oelz O. (1990). Prevalence of acute mountain sickness in the Swiss Alps. BMJ (Clin Res Ed.) 301:853-855.
81. Maggiorini M, Müller A, Hofstetter D, Bärtsch P, and Oelz O. (1998). Assessment of acute mountain sickness by different score protocols in the Swiss Alps. Aviat Space Environ Med 69:1186-1192.
82. Maggiorini M, Brunner-La Rocca H-P, Peth S, Fischler M, Böhm T, Bernheim A, Kiencke S, Bloch KE, Dehnert C, Naeije R, Lehmann T, Bartsch P, and Mairbaurl H. (2006). Both tadalafil and dexamethasone may reduce the incidence of high-Altitude pulmonary edema: A randomized trial. Ann Int Med 145:497-506.
83. Mairer K, Wille M, Bucher T, and Burtscher M. (2009). Prevalence of acute mountain sickness in the Eastern Alps. High Alt Med Biol 10:239-245.
84. Mairer K, Wille M, and Burtscher M. (2010).The prevalence of and risk factors for acute mountain sickness in the Eastern and Western Alps. High Alt Med Biol 11:343-348.
85. Meyer J. (2012). Twice-daily assessment of trekkers on Kilimanjaros Machame route to evaluate the incidence and timecourse of acute mountain sickness. High Alt Med Biol 13: 281-284.
86. Mistry G, Chandrashekhar Y, Sen U, and Anand IS. (1993). Study of acute mountain sickness during rapid ascent trekking to extreme altitude. J Assoc Physicians India 41:500-502.
87. Montgomery AB, Luce JM, Michael P, and Mills J. (1989). Effects of dexamethasone on the incidence of acute mountain sickness at two intermediate altitudes. JAMA: 261:734-736.
88. Moraga FA, Flores A, Serra J, Esnaola C, and Barriento C. (2007). Ginkgo biloba decreases acute mountain sickness in people ascending to high altitude at Ollagüe (3696 m) in northern Chile. Wilderness Environ Med 18:251-257.
89. Moraga FA, Osorio JD, and Vargas ME. (2002). Acute mountain sickness in tourists with children at Lake Chungará (4400 m) in northern Chile. Wilderness Environ Med 13:31-35.
90. Moraga FA, Pedreros CP, and Rodríguez CE. (2008). Acute mountain sickness in children and their parents after rapid ascent to 3500m (Putre, Chile). Wilderness Environ Med 19:287-292.
91. Murdoch DR. (1995). Symptoms of infection and altitude illness among hikers in the Mount Everest Region of Nepal. Aviat Space Environ Med 66:148-151.
92. Murdoch DR, and Curry C. (1998). Acute mountain sickness in the southern Alps of New Zealand. N Zealand Med J 111:168-169.
93. Muza SR, Kaminsky D, Fulco CS, Banderet LE, and Cymerman A. (2004). Cysteinyl leukotriene blockade does not prevent acute mountain sickness. Aviat Space Environ Med 75:413-419.
94. Myers SD, Biccard BM, Chan C, Imray CHE, Wright AD, Pattinson KTS, and Birmingham Medical Research Expeditionary Society. (2008). Delayed acclimatization of the ventilatory threshold in healthy trekkers. Wilderness Environ Med 19:124-128.
95. Netzer N, Strohl K, Faulhaber M, Gatterer H, and Burtscher M. (2013). Hypoxia-related altitude illnesses. J Travel Med 20:247-255.
96. Newcomb L, Sherpa C, Nickol A, and Windsor J. (2011).A comparison of the incidence and understanding of altitude illness between porters and trekkers in the Solu Khumbu Region of Nepal. Wilderness Environ Med 22:197-201.
97. Pesce C, Leal C, Pinto H, González G, Maggiorini M, Schneider M, and Bärtsch P. (2005).Determinants of acute mountain sickness and success on Mount Aconcagua (6962 m). High Alt Med Biol 6:158-166.
98. Pradhan S, Yadav S, Neupane P, and Subedi P. (2009). Acute mountain sickness in children at 4380 meters in the Himalayas. Wilderness Environ Med 20:359-363.
99. Regard M, Landis T, Casey J, Maggiorini M, Bärtsch P, and Oelz O. (1991). Cognitive changes at high altitude in healthy climbers and in climbers developing acute mountain sickness. Aviat Space Environ Med 62:291-295.
100. Ren Y, Fu Z, Shen W, Jiang P, He Y, Peng S, Wu Z, and Cui B. (2010). Incidence of high altitude illnesses among unacclimatized persons who acutely ascended to Tibet. High Alt Med Biol 11:39-42.
101. Rexhaj E, Garcin S, Rimoldi SF, Duplain H, Stuber T, Allemann Y, Sartori C, and Scherrer U. (2011). Reproducibility of acute mountain sickness in children and adults: A prospective study. Pediatrics 127:e1445-1448.
102. Richalet JP, Donoso MV, Jiménez D, Antezana A-M, Hudson C, Cortès G, Osorio J, and Leon A. (2002). Chilean miners commuting from sea level to 4500 m: A prospective study. High Alt Med Biol 3:159-166.
103. Roach RC, Houston CS, Honigman B, Nicholas RA, Yaron M, Grissom CK, Alexander JK, and Hultgren HN. (1995). How well do older persons tolerate moderate altitude? West J Med 162:32-36.
104. Roach RC, Larson EB, Hornbein TF, Houston CS, Bartlett S, Hardesty J, Johnson D, and Perkins M. (1983). Acute mountain sickness, antacids and ventilation during rapid, active ascent of Mount Rainier. Aviat Space Environ Med 54:397-401.
105. Roach RC, Bärtsch P, and Oelz O. (1993). Lake Louise AMS Scoring Consensus Commitee: The Lake Louise Acute Mountain Sickness Scoring System. In: Hypoxia and Molecular Medicine: Proceedings of the 8th International Hypoxia Symposium Held at Lake Louise, Canada, February 9-13, 1993, by John R. Sutton, Charles S. Houston, and Geoff Coates, Burlington, VT: Queen City Printers. pp. 272-274.
106. Roach R, and Kayser B. (2007). Measuring mountain maladies. High Alt Med Biol 8: 171-172.
107. Rock PB, Johnson TS, Larsen RF, Fulco CS, Trad LA, and Cymerman A. (1989). Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest 95:568-573.
108. Rock PB, Johnson TS, Cymerman A, Burse RL, Falk LJ, and Fulco CS. (1987). Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4, 300 m). Aviat Space Environ Med 58:668-672.
109. Roeggla G, Roeggla M, Podolsky A, Wagner A, and Laggner AN. (1996). How can acute mountain sickness be quantified at moderate altitude? J Royal Soc Med 89:141-143.
110. Röggla G, Wagner A, and Röggla M. (1992). Is the incidence of acute mountain sickness (AMS) at medium altitude in the Austrian Alps influenced by the height of home residence of the alpinist? Acta Medica Hungarica 49:233-238.
111. Salazar H, Swanson J, Mozo K, White AC Jr, and Cabada MM. (2012). Acute mountain sickness impact among travelers to Cusco, Peru. J Travel Med 19:220-225.
112. Schneider M, Bernasch D, Weymann J, Holle R, and Bartsch. (2002). Acute mountain sickness: Influence of susceptibility, preexposure, and ascent rate. Med Sci Sports Exercise 34: 1886-1891.
113. Shah MB, Braude D, Crandall CS, Kwack H, Rabinowitz L, Cumbo TA, Basnyat B, and Bhasyal G. (2006). Changes in metabolic and hematologic laboratory values with ascent to altitude and the development of acute mountain sickness in Nepalese pilgrims. Wilderness Environ Med 17:171-177.
114. Silber E, Sonnenberg P, Collier DJ, Pollard AJ, Murdoch DR, and Goadsby PJ. (2003). Clinical features of headache at altitude: A prospective study. Neurology 60:1167-1171.
115. Stokes S, Kalson NS, Earl M, Whitehead AG, Tyrrell-Marsh I, Frost H, and Davies A. (2010). Age is no barrier to success at very high altitudes. Age Ageing 39:262-265.
116. Subudhi AW, Panerai RB, and Roach RC. (2010). Effects of hypobaric hypoxia on cerebral autoregulation. Stroke 41:64646.
117. Talbot NP, Smith TG, Privat C, Nickol AH, Rivera-Ch M, León-Velarde F, Dorrington KL, and Robbins PA. (2011). Intravenous iron supplementation may protect against acute mountain sickness: A randomized, double-blinded, placebocontrolled trial. High Alt Med Biol 12:265-269.
118. Talbot TS, Townes DA, and Wedmore IS. (2004). To air is human: Altitude illness during an expedition length adventure race. Wilderness Environ Med 15:90-94.
119. Tang E, Chen Y, and Luo Y. (2014). Dexamethasone for the prevention of acute mountain sickness: Systematic review and meta-Analysis. Intl J Cardiol 173:133-138.
120. Theis MK, Honigman B, Yip R, McBride D, Houston CS, and Moore LG. (1993). Acute mountain sickness in children at 2835 meters. Am J Dis Children (1960) 147:143-145.
121. Tissot van Patot MC, Leadbetter G, Keyes LE, Bendrick-Peart J, Beckey VE, Christians U, and Hackett P. (2005). Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness. J Appl Physiol (Bethesda, Md.: 1985) 98:1626-1629.
122. Tissot Van Patot, MC, Leadbetter G, Keyes LE, Maakestad KM, Olson S, and Hackett PH. (2008). Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Alt Med Biol 9:289-293.
123. Tsianos G, Woolrich-Burt L, Aitchison T, Peacock A, Watt M, Montgomery H, Watt I, and Grant S. (2006). Factors affecting a climbers ability to ascend Mont Blanc. Eur J Appl Physiol 96:32-36.
124. Utz G, Schlierf, Barth, Linhart, and Wollenweber. (1970). [Prevention of acute mountain sickness using acetazolamide]. Münchener Med Wochenschrift (1950) 112:1122-1124.
125. Vardy J, Vardy J, and Judge K. (2006). Acute mountain sickness and ascent rates in trekkers above 2500m in the Nepali Himalaya. Aviat Space Environ Med 77:742-744.
126. Wagner DR, DZatko K, Tatsugawa K, Murray K, Parker D, Streeper T, and Willard K. (2008). Mt. Whitney: Determinants of summit success and acute mountain sickness. Med Sci Sports Exercise 40:1820-1827.
127. Wagner DR, Fargo JD, Parker D, Tatsugawa K, and Young TA. (2006). Variables contributing to acute mountain sickness on the summit of Mt Whitney. Wilderness Environ Med 17:221-228.
128. Wagner DR, Teramoto M, Knott JR, and Fry JP. (2012). Comparison of scoring systems for assessment of acute mountain sickness. High Alt Med Biol 13:245-251.
129. Wang J, Ke T, Zhang X, Chen Y, Liu M, Chen J, and Luo W. (2013). Effects of acetazolamide on cognitive performance during high-Altitude exposure. Neurotoxicol Teratol 35:28-33.
130. Wang S-H, Chen Y-C, Kao W-F, Lin Y-J, Chen J-C, Chiu T-F, Hsu T-Y, Chen H-C, and Liu S-W. (2010). Epidemiology of acute mountain sickness on Jade Mountain, Taiwan: An annual prospective observational study. High Alt Med Biology 11:43-49.
131. West JB, Schoene RB, Luks A, and Milledge JS. (2013). High Altitude Medicine and Physiology. 5th ed. Boca Raton; London: CRC Press.
132. Willmann G, Fischer MD, Schatz A, Schommer K, Messias A, Zrenner E, Bartz-Schmidt KU, and Gekeler F. (2011). Quantification of optic disc edema during exposure to high altitude shows no correlation to acute mountain sickness. PloS One 6 :e27022.
133. Wu TY, Ding SQ, Liu JL, Yu MT, Jia JH, Duan JQ, Chai CZ, Dai RC, Zhang SL, Liang BZ, Zhao JZ, Qi DT, Sun YF, and Kayser B. (2009). Reduced incidence and severity of acute mountain sickness in Qinghai-Tibet railroad construction workers after repeated 7-month exposures despite 5-month low altitude periods. High Alt Med Biol 10:221-232.
134. Wu TY, Ding SQ, Liu JL, Yu MT, Jia JH, Chai ZC, Dai RC, Zhang SL, Li BY, Pan L, Liang BZ, Zhao JZ, Qi DT, Sun YF, and Kayser B. (2007). Who should not go high: Chronic disease and work at altitude during construction of the Qinghai-Tibet Railroad. High Alt Med Biol 8:88-107.
135. Wu, TY, Ding SQ, Liu JL, Jia JH, Chai ZC, and Dai RC. (2012). Who are more at risk for acute mountain sickness: A prospective study in Qinghai-Tibet railroad construction workers on Mt. Tanggula. Chin Med J 125:1393-1400.
136. Wu TY, Ding SQ, Liu JL, Jia JH, Chai ZC, Dai RC, JZ, Tang QD, and Kayser B. (2012).Smoking, acute mountain sickness and altitude acclimatisation: A cohort study. Thorax 67:914-919.
137. Yaron M, Waldman N, Niermeyer S, Nicholas R, and Honigman B. (1998). The diagnosis of acute mountain sickness in preverbal children. Arch Pediatr Adolesc Med 152:683-687.
138. Yaron M, Niermeyer S, Lindgren KN, and Honigman B. (2002). Evaluation of diagnostic criteria and incidence of acute mountain sickness in preverbal children. Wilderness Environ Med 13:21-26.
139. Zell SC, and Goodman PH. (1988). Acetazolamide and dexamethasone in the prevention of acute mountain sickness. West J Med 148:541-545.
140. Ziaee V, Yunesian M, Ahmadinejad Z, Halabchi F, Kordi R, Alizadeh R, and Afsharjoo HR. (2003). Acute mountain sickness in Iranian trekkers around Mount Damavand (5671 m) in Iran. Wilderness Environ Med 14:214-219.